Login

Recent searches

No recent searches

Search options

Only available when logged in.
mastodon.online is one of the many independent Mastodon servers you can use to participate in the fediverse.
A newer server operated by the Mastodon gGmbH non-profit

Administered by:

Server stats:

11K
active users

mastodon.online: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.4.0-nightly.2025-03-25

#COVID19

180 posts135 participants3 posts today
Public *
Hannu Ikonen, MD

Fuck Tim Walz.

Hes a Collaborator too far as im concerned.

"Democratic Governor Tim Walz does Trumpian Return To Office.

We all know that RTO is fossil fueled and caters to commercial real estate to get butts in seats downtown for The Economy. This is NOT a progressive move and Walz should be shamed harshly by Democrat voters in Minnesota for acting like a right-winger on telework.

'Gov. Walz announce change to state telework policy By WDIO Minnesota Governor Tim Walz announced an update to the state’s telework policy for state workers. The change would require most state agency employees to work in-person for at least 50% of their scheduled work days. This would go in effect on June 1, 2025. “This approach balances the flexibility of telework with the workplace advantages of being in office,” said Gov. Walz. “Having more state employees in the office means that collaboration can happen more quickly and state agencies can build strong organizational cultures more easily.” '

That collaboration nonsense is all bullshit and we all know it by now. Anti-telework is just collaborating with right-wing business interests."

-Chloe from Scranton Team Humans Newsletter

wdio.com/front-page/top-storie

#Covid19#RTO#LiberalsAreDogshit
Public
ahimsa

"COVID gave rise to vaccine skepticism. That may affect preparedness for next pandemic"

opb.org/article/2025/03/29/cov

"One of the most prominent spreaders of misleading content about vaccines was Robert F. Kennedy Jr., who formerly led Children’s Health Defense, an anti-vaccination nonprofit, and is now Trump’s secretary of health and human services."

Those with negative views toward COVID-19 vaccines are increasingly negative about other vaccines too, research by Motta and others has found. One in four Republican parents is now skipping or delaying some childhood vaccines for their kids, such as the MMR vaccine that protects against measles, according to a study from KFF, a nonprofit health policy organization.
#USPol#Covid19#Vaccines
Public
Ms. Opossum graphs COVID data.

UPDATED: #Ontario #SARSCoV2 variants.

Of 50 samples from 3/2 - 3/8:
XEC.*: 22% (⬇️ 37.6%)
LP.8.1.*: 20% (⬇️ 30.1%)
KP.3.3.2.* (incl. NP.1): 20% (⬆️ 5.8%)
LF.7.7.2: 24% (⬆️ 3.5%)

ratnegative.tumblr.com/ONVaria #COVID19

-----------

Of the samples collected in Ontario on these weeks, the prevalence of each of these significant variants/lineages are as follows:

- 3/2 - 3/8 -
• XEC.*: 22%
• JN.1.11.1.*: 48%
→ LP.8.1.* (incl. LP.8.1.1): 20%
→ KP.3.* (only KP.3.1.1.*, ".3.3.2.*): 28%
→ KP.3.1.1.* (incl. MC.1.2, ".21.1): 8%
→ KP.3.3.2.* (incl. NP.1): 20%
→ NP.1: 4%
• JN.1.16.1.* (incl. LF.7.2.1, ".7.7.2): 28%
→ LF.7.7.2: 24%

- 2/23 - 3/1 -
• XEC.*: 37.6%
• JN.1.11.1.*: 49.7%
→ LP.8.1.* (incl. LP.8.1.1.*): 30.1%
→ KP.3.* (only KP.3.1.1.*, NP.1 ctd.) †: 19.7%
→ KP.3.1.1.* (incl. MC.1.*, ".10.*, ".13.*, ".24, ".31): 13.9%
→ MC.1.* (incl. MC.1.2, ".1.6, ".1.7): 6.9%
→ KP.3.3.2.* (only NP.1 ctd.): 5.8%
• JN.1.16.1.* (incl. LF.7.2.1, ".7.7.*): 5.8%
→ LF.7.7.2: 3.5%

† 1 KP.3.3.2 & 1 KP.3.3.5 sample ctd. as JN.1.*

X.X.* in text = X.X & descendants.

X.X.* in graph = all descendants of X.X, except for ones with own segment of week’s bar.

Public
datum (n=1)

"Province continues to ensure people are protected from COVID-19, measles" says the press release

simultaneously they removed the mask mandate from healthcare settings, haven't yet made C19 vaccines available (and are tepid at best that "non-vulnerable people" (ha ha only morbid) can or should get boosted), C19 vaccination protection still wanes incredibly fast.

:unsure_fry:

#COVIDIsNotOver#BCPoli#BC
Public
ABC Feeds

Bird flu is ravaging egg supply, but a deadlier strain is coming from overseas
By Catherine Taylor

Since 1959 the avian flu virus H5N1 has been popping up around the globe. Now scientists believe it could spark the next pandemic.

abc.net.au/news/2025-03-30/nex

ABC News · With H5N1 2.3.4.4b causing chaos overseas, the hunt for the next pandemic is on our shoresBy Catherine Taylor
#AvianInfluenza#EpidemicsandPandemics#Birds
Public
Joop #LoCovid #NoPlanetB

#locovid #ABCovid #qp2t
Uitstekend weekbericht 2025-12 over status & impact van #Covid19, door Maria: locovid.nl/oversterfte-ziekte-

Het SARS2 besmettingsrisico is nog relatief laag, maar duidelijk door het dal heen. Griep is op zijn retour, maar andere (infectie)ziekten steken de kop op: tuberculose, gordelroos, mazelen.

Veel aandacht voor de neurologische schade door Covid: hersenmist, concentratie- en geheugenproblemen, verhoogd risico op dementie.

Artikel kop in Washington Post van 28-3-2025: "Something was wrong with my brain” How covid leaves its mark on cognition Five years after the pandemic began, the neurocognitive effects of long covid are numerous and troubling. And some of these cognitive losses may extend to people who quickly recovered. Today at 6:00 a.m. EDT
Public
Augie Ray

STUDY in Africa found that #COVID19 reinfection could occur "within remarkably short intervals of less than three weeks." The reinfections occurred "predominantly among unvaccinated individuals and those under 18 years of age."

medrxiv.org/content/10.1101/20

medRxiv · Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: Insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic waveBetween November 2023 and March 2024, coastal Kenya experienced a new wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (total 185 positive samples) residing in the Kilifi Health and Demographic Surveillance (KHDSS) area (∼900 km2). Sixteen SARS-CoV-2 lineages within three sub-variants (XBB.2.3-like (58.4%), JN.1-like (40.5%) and XBB.1-like (1.1%)) were identified. Symptomatic infection rate was estimated at 16.0% (95% CI 11.1%-23.9%) based on community testing regardless of symptom status, and did not differ across the sub-variants ( p = 0.13). The most common infection symptoms in community cases were cough (49.2%), fever (27.0%), sore throat (7.3%), headache (6.9%), and difficulty in breathing (5.5%) and one case succumbed to the infection. Genomic analysis of the virus from serial positives samples confirmed repeat infections among five participants under follow-up (median interval 21 days, range 16-95 days); in four participants, the same virus lineage was responsible in both the first and second infections, while one participant had a different lineage in the second infection compared to the first. Phylogenetic analysis including >18,000 contemporaneous global sequences estimated that at least 38 independent virus introduction events occurred into the KHDSS area during the wave, the majority likely originating in North America and Europe. Our study highlights coastal Kenya, like most other localities, continues to face new SARS-CoV-2 infection waves characterized by the circulation of new variants, multiple lineage importations and reinfections. Locally the virus may circulate unrecognized as most infections are asymptomatic in part due to high population immunity after several waves of infection. Our findings highlight the need for sustained SARS-CoV-2 surveillance to inform appropriate public health responses such as scheduled vaccination for risk populations. Author summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has transitioned to an endemic respiratory pathogen causing seasonal outbreaks. We examined the epidemiological and genomic patterns of a wave of SARS-CoV-2 infections in coastal Kenya that occurred between November 2023 and March 2024. By analyzing genetic and epidemiological data from positive cases in Kilifi, we inferred the origins of the new strains, documented repeat infections and the virus’ ongoing evolution. Our data revealed several variants circulating in the community, indicating multiple new virus introductions probably before and during local outbreaks. Many infected individuals were asymptomatic, highlighting unnoticed transmission within the population. Despite low vaccination rates among the cases (∼7.0%), high population immunity has previously been reported locally. The common symptoms among those who were symptomatic included cough, fever, and sore throat. A few participants experienced repeat infections during the wave, often involving closely related strains. The virus lineages detected were most closely related to those sampled in Europe. Our findings emphasize that, despite the end of the emergency phase, SARS-CoV-2 remains a significant public health issue, necessitating ongoing monitoring and responsive measures e.g. target vaccinations, masking and good hygiene practices to protect those at risk of severe infection. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was funded by Wellcome through (a) a Career Development Award to CNA (Ref. #226002/A/22/Z & Ref. #226002/Z/22/Z) and (b) 226130/Z/22/Z from the Wellcome Covid19: understanding the biological significance of SARS CoV 2 variants application to IO. SD acknowledges support from the Fonds National de la Recherche Scientifique (F.R.S.FNRS, Belgium; grant nF.4515.22), from the Research Foundation, Flanders (Fonds voor Wetenschappelijk Onderzoek, Vlaanderen, FWO, Belgium; grant nG098321N), and from the European Union Horizon 2020 projects MOOD (grant agreement n874850) and LEAPS (grant agreement n101094685). E.C.H. is supported by a National Health and Medical Research Council (Australia) Investigator Grant (GNT2017197). AWL was supported by the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) which is funded by the Science for Africa Foundation [Del22007] with support from Wellcome Trust and the UK Foreign, Commonwealth & Development Office and is part of the EDCPT2 programme supported by the European Union; the Bill & Melinda Gates Foundation [INV033558]; and Gilead Sciences Inc., [19275]. All content contained within is that of the authors and does not necessarily reflect positions or policies of any SANTHE funder. For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of KEMRI Scientific Ethics and Research Unit (SERU), Nairobi Kenya gave ethical approval for this work. Each surveillance platform (community, outpatient, and inpatient) that provided samples analysed here had a dedicated research protocol. The protocols consenting and sample collection process were reviewed and approved by KEMRI Scientific Ethics and Research Unit (SERU), Nairobi Kenya (protocol numbers #3178, #3103 and 4724). Samples were collected following consent from a parent or guardian for participants aged <18 year olds (with assent for children aged between 13 to 18 year olds). Individual written informed consent was sought for participants aged >18 years. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The final consensus genomes from the SARS-CoV-2 samples sequenced in this study have been deposited in the Global Initiative on Sharing all Influenza Data (GISAID) database and can be accessed at <https://doi.org/10.55876/gis8.250116pz>. Epidemiological data and scripts for data analysis are available on the Harvard dataverse <https://doi.org/10.7910/DVN/BMCJTI>.
Public
Bytes Europe

Houston Health Department loses $42 million after federal COVID-19 grants canceled in Texas; job cuts expected to follow byteseu.com/874125/ #Budget #COVIDFunding #COVID19 #DepartmentOfGovernmentAndEfficiency #doge #FederalSpending #HarrisCounty #Health #Houston #money #ReliefGrants #texas #TexasDepartmentOfStateHealthServices

Bytes Europe · Houston Health Department loses $42 million after federal COVID-19 grants canceled in Texas; job cuts expected to followHOUSTON – The Texas Department of State Health Services (DSHS) is reaching out to counties using COVID-era grants to stop spending those funds as it evaluates $877 million in grant cancelations by the federal government.The Houston Health Department confirmed with KPRC 2 that they are losing $42 million. The decision comes from the U.S. Department of Health and Human Services, which oversees the grants.The funds, originally intended for pandemic relief, are one of many federal funds under the Trump Administration that have been pulled back.SEE ALSO: Trump administration says it will pull back billions in COVID funding from local health
Public
Mike Honey

Here's the latest variant picture for Europe (excluding the UK), to early March.

The XEC.* variant remains dominant, but it has declined to around 31% frequency.

The LP.8.1.* variant grew to around 23%.

Note the recent sample volumes are very low, so this might not be a representative picture.

#COVID19 #EUR #XEC #LP_8_1
🧵

Public
Mike Honey

Here's the latest variant picture for Canada. Some further samples been shared from Ontario but they are thin and patchy compared to the earlier volumes.

The current picture is that XEC.* is stall dominant at 30-40%, with LP.8.1.* challenging at around 24%. The JN.1.* + FLiRT lineages are at 10-12%.

#COVID19 #Canada #XEC #LP_8_1
🧵

ExploreLive feeds
About